Palani Balu Email & Phone Number

Alameda, California, Us

Redwood City, California, Us

San Diego, California, Us

Involved in design, synthesis, and analysis of antibody oligonucleotide conjugates (AOC) for muscle diseases. Performed process scale purification and mew method development for the AOC analysis. Earlier, involved in the design, synthesis, and analysis of nanoparticles.

New York, New York, Us

Expertise in antibody purification; synthesis, purification, and characterization of antibody drug conjugates (ADC); bispecific antibody for oncology and metabolic projectsMember of Pfizer (CovX) Management Team, CovX Scientific Advisory Committee (CSA), and Pfizer Biophysical Characterization Steering Committee, and Pfizer Bioconjugation NetworkFiled a PCT and a US patent Anti-diabetic drugs (To be published in June 2013)Supervised a senior scientist and a senior research associate

Developed new separation methods for complex carbohydrate excipients and proteins (RP-HPLC and SEC (with UV and CAD), SDS-PAGE, and ELISA)Performed preformulation, stability, and in vitro release study of spray-dried and freeze-dried proteins, and small molecules (subcutaneous sustained drug delivery)Identified Protein – Excipient interactions and modifications (LC/MS, MS/MS, MALDI/MS, ICPMS, 1H, and 13C NMR)Authored a technical report: “Sucrose Acetate Isobutyrate (SAIB) – Synthesis, structure, sub-groups, positional isomers, purification, and analytical methods”Collaborated in SABER, PLA, and PLGA drug delivery technology and co-authored a book chapter on this topicCo-authored a publication and a patent applicationSupervised and guided two research associates

Emeryville, California, Us

Developed methods and validations to enhance quality control for RP-HPLC and SEC (Interferon-ß, IL-2, and anti CD40)Experience in GMP Lab with the following assays transferred to different sites: ELISA, Western Blot, SDS-PAGE, Lys-C Digest, HSA, Karl Fischer, and USP ParticulatePerformed particulate analysis by Scanning Electron Microscope (SEM) and Fourier Transform Infrared Spectroscopy (FTIR), Validation of SEM and Total Organic Carbon Analysis (TOC)Supervised and guided two research associates

Discovered separation methods for proteins and virus particles previously unknown: RP-HPLC and SEC (with UV detector and MALSD), SDS-PAGE, Western Blot, and ELISAExplored and implemented novel biophysical approaches to study influenza and parainfluenza virus particles in attempt to separate infectious and non-infectious virionsDeveloped rapid 10-minute method to separate and quantify influenza virus particles from complex matrices using SEC currently utilized in quality control and manufacturing Concentrated and purified virus particles of interest by CFF that resulted in 95% recovery of infectivity (Egg Derived, Vero Cells, and MDCK Cells)Contributed to validation of novel biophysical methods (SEC, CFF) using assays such as SDS-PAGE, Western Blot, Real-time PCR, Neuraminidase assay, Hemagglutination assay, Tissue Culture Infectious Dosage (TCID50) assay and in vivo models (Ferret model). Recoveries of biologically active virus particles were shown to be 80% to 90%Modified SEC method and implemented to separate virus particles to separate sub-components of influenza virus such as hemagglutinin (HA) and neuraminidase (NA) Evaluated MALSD, FFF, Disc Centrifugation (DF), and Analytical Ultra Centrifugation (AUC) for characterization and analysis of virus particlesPublished 6 patents and a paperSupervised and guided a research associate

Designed, optimized and synthesized peptide ligands as therapeutic molecules for diseases such as thrombocytopenia, sickle cell anemia, asthma, and inflammation. Random Phage Display (RPD) technology was used to discover novel ligand peptides and further optimized bioactivity and stabilityPublished 14 patents and 7 papersLed group comprising a scientist and three research associates primarily focused on:Lead optimization by elucidating novel peptides structures using ES/MS and MALDI/MS Increased therapeutic peptide half-life using pegylation and validated by in vitro studies Optimized initial hits to lead peptide compounds directed to Erythropoietin (EPO), Thrombopoietin (TPO), Vascular Endothelial Growth Factor Receptor (VEGFR-2), Stem Cell Factor (SCF), Granulocyte Colony Stimulating Factor (GCSF), Transforming Growth Factor (TGF), and Interleukins (IL) such as IL-1, IL-2, IL-5 and IL-16Member of Senior Staff Committee – Participated in project evaluation and budgetary process